Precision Peptide closes $2M private placement of common shares

The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) has closed a non-brokered private placement of common shares, raising gross proceeds of $2,000,000 through the issuance of 4,000,000 shares at $0.50 per share.

The offering was conducted under the Listed Issuer Financing Exemption pursuant to Part 5A of National Instrument 45-106 - Prospectus Exemptions, and was available to purchasers resident in all Canadian provinces except Quebec. The securities issued are not subject to a hold period under applicable Canadian securities laws. No finder's fees were paid in connection with the transaction.

The company stated it intends to use the net proceeds for general working capital, advancing business objectives, funding marketing initiatives, and supporting inventory and product procurement.

The Precision Peptide Company describes itself as a wellness company focused on peptide formulations and delivery systems, with products manufactured in a U.S. facility and distributed across North America.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Artiva Biotherapeutics, Inc. (ARTV) Misses Q2 EPS by 63c
• Rio Grande Resources plans $2.5M private placement financing